News & Updates

The selective neurokinin (NK)-1,3 receptor antagonist elinzanetant appears to be beneficial in the treatment of vasomotor symptoms (VMS) and associated sleep disturbance in postmenopausal women, as shown in the results of the phase IIb SWITCH-1 trial.

Coronary artery disease appears to be common among women with a history of adverse pregnancy outcomes, including those estimated to be at low risk of cardiovascular disease, according to a study.

The use of buprenorphine during pregnancy appears to be associated with a lower risk of adverse neonatal outcomes compared with methadone use. However, adverse maternal outcomes are similar for both therapies, according to a recent study.

The use of letrozole for inducing ovulation in women with infertility and polycystic ovarian syndrome (PCOS) appears to yield improvements in ovulation, pregnancy, and live-birth rates as compared with clomiphene citrate, according to a study.

New drug applications approved by US FDA as of 16-31 January 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Women with vulvovaginal atrophy exhibit a less favourable vaginal microbiome than healthy postmenopausal women, but ospemifene may restore vaginal health by reducing potentially harmful bacteria, as shown in a study.

Children conceived by their parents through non-in vitro fertilization fertility treatment show no metabolic difference from those conceived spontaneously, according to a study.